ACADIA Pharmaceuticals Inc (ACAD) Dividends

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 796 full-time employees. The company went IPO on 2004-05-27. The firm is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. The company is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.